Efficacy of trastuzumab in treatment of disseminated HER2-positive ductal adenocarcinoma of the submandibular gland (a case report)

A. M. Mudunov; Мудунов А. М.; I. M. Gelfand; Гельфанд И. М.; O. D. Ryzhova; Рыжова О. Д.; M. B. Pak; Пак М. Б.; A. S. Tarakanova; Тараканова А. С.; Tarakanov; Тараканов И. О.; A. S. Morozova; Морозова А. С.; H. Chen; Чэнь Х.

doi:10.17650/2222-1468-2025-15-3-131-139

Efficacy of trastuzumab in treatment of disseminated HER2-positive ductal adenocarcinoma of the submandibular gland (a case report)

Authors: Mudunov A.M.¹^,2, Gelfand I.M.³, Ryzhova O.D.⁴, Pak M.B.⁵, Tarakanova A.S.², Tarakanov ², Morozova A.S.⁶, Chen H.⁷
Affiliations:
1. Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
2. Sechenov University, Ministry of Health of Russia
3. Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies, Federal Medical and Biological Agency of Russia
4. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
5. Specialized Medical Center of the Bank of Russia
6. Clinic “K+31”
7. Beijing Chao-Yang hospital, Capital Medical University
Issue: Vol 15, No 3 (2025)
Pages: 131-139
Section: CASE REPORT
Published: 03.11.2025
URL: https://ogsh.abvpress.ru/jour/article/view/1112
DOI: https://doi.org/10.17650/2222-1468-2025-15-3-131-139
ID: 1112

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Ductal adenocarcinoma of the gland is a rare malignancy characterized by high rate of metastasis and poor survival. Immunohistochemical findings indicate that 40 % of patients demonstrate overexpression of the human epidermal growth factor receptor 2 (HER2) (2–3+). In patients with distant metastases, targeted anti-HER2 therapy is the only effective method.

This article describes our experience of successful targeted therapy in a patient with HER2-positive ductal adenocarcinoma of the submandibular gland.

Keywords

submandibular gland, ductal adenocarcinoma, epidermal growth factor receptor type 2, distant metastases, trastuzumab, paclitaxel

About the authors

A. M. Mudunov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; Sechenov University, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-0918-3857

111 1st Uspenskoe Shosse, Lapino, Moscow Region 143081

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

I. M. Gelfand

Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies, Federal Medical and Biological Agency of Russia

Author for correspondence.
Email: igorgelf@yandex.ru
ORCID iD: 0000-0002-4496-6128

Igor Mikhailovich Gelfand

28 Orekhovy Bul’var, Moscow 115682

Russian Federation